ABT-963 [2-(3,4-difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4- methanesulfonyl-phenyl)-2H-pyridazin-3-one], A highly potent and selective disubstituted pyridazinone cyclooxgenase-2 inhibitor

Journal of Pharmacology and Experimental Therapeutics

Volumn 311, Issue 3, 2004, Pages 904-912

  Harris, Richard R ^a   Black, Lawrence ^a   Surapaneni, Sekhar ^a   Kolasa, Teodozyj ^a   Majest, Sandra ^a   Namovic, Marian T ^a   Grayson, George ^a   Komater, Victoria ^a   Wilcox, Denise ^a   King, Linda ^a   Marsh, Kennan ^a   Jarvis, Michael F ^a   Nuss, Merrill ^a   Nellans, Hugh ^a   Pruesser, Lee ^a   Reinhart, Glenn A ^a   Cox, Bryan ^a   Jacobson, Peer ^a   Stewart, Andrew ^a   Coghlan, Michael ^a   Carter, George ^a   Bell, Randy L ^a   more..

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3,4 DIFLUOROPHENYL) 4 (3 HYDROXY 3 METHYLBUTOXY) 5 (4 METHANESULFONYLPHENYL) 2H PYRIDAZIN 3 ONE; 5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; A 241611; A 282904; ABT 963; BENZENE DERIVATIVE; CARRAGEENAN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; FLUORINE DERIVATIVE; HETEROCYCLIC COMPOUND; INDOMETACIN; MESYLIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRIDAZINONE DERIVATIVE; ROFECOXIB; UNCLASSIFIED DRUG; VALDECOXIB;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DESTRUCTION; DISEASE ASSOCIATION; DISTRIBUTION VOLUME; DOG; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG SOLUBILITY; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; HYPERALGESIA; IN VIVO STUDY; INFLAMMATION; MALE; NOCICEPTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOLYSIS; PAIN; PAW EDEMA; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RAT; SOFT TISSUE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CARRAGEENAN; CENTRAL NERVOUS SYSTEM DISEASES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOGS; EDEMA; EICOSANOIDS; HEAT; HYPERALGESIA; INTERLEUKIN-1; ISOENZYMES; MALE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; PYRIDAZINES; RATS; RATS, INBRED LEW; RATS, SPRAGUE-DAWLEY; RECEPTORS, DRUG; STOMACH ULCER; SULFONES;

EID: 10044298330     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.070052     Document Type: Article

References (31)

1. Baenziger NL and Majerus PW (1974) Isolation of human platelets and platelet surface membranes Methods Enzymol 31:149-155.
2. Bingham CO 3rd (2002) Development and clinical application of COX-2-selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis. Cleve Clin J Med 69 (Suppl 1):SI5-SI12.
3. Capone ML, Tacconelli S, Sciulli MG, and Patrignani P (2003) Clinical pharmacology of selective COX-2 inhibitors. Int J Immunopathol Pharmacol 16 (Suppl 2):49-58.
4. Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, et al. (1999) Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)- furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 290:551-560.
5. Copeland RA, Williams JM, Giannaras J, Nurnberg S, Covington M, Pinto D, Pick S, and Trzaskos JM (1994) Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci USA 91:11202-11206.
6. de Brito FB (1989) Pleurisy and pouch models of acute inflammation, in Pharmacological Methods in the Control of Inflammation (Chang JY and Lewis AJ eds) pp 173-194, Alan Liss Inc., New York.
7. Everts B, Wahrborg P, and Hedner T (2000) COX-2-specific inhibitors-the emergence of a new class of analgesic and anti-inflammatory drugs. Clin Rheumatol 19:331-343.
8. Gans KR, Galbraith W, Roman RJ, Haber SB, Kerr JS, Schmidt WK, Smith C, Hewes WE, and Ackerman NR (1990) Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther 254:180-187.
9. Garavito RM, Malkowski MG, and DeWitt DL (2002) The structures of prostaglandin endoperoxide H synthases-1 and -2 Prostaglandins Other Lipid Mediat 68-69:129-152.
10. Grossman CJ, Wiseman FS, Trevethick MA, and Birch PJ (1995) Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDS and Cox 2 inhibitors. Inflamm Res 44:252-257.
11. Hargreaves K, Dubner R, Brown F, Flores C, and Joris J (1988) A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32:77-88.
12. Herschman HR (1996) Prostaglandin synthase 2. Biochim Biophys Acta 1299:125-140.
13. Hulkower K, Otis E, Li J, Bell R, and Carter G (1997) Induction ofprostaglandin H synthase-2 by tumour necrosis factor-alpha in human WISH cells. J Pharmacol Exp Ther 280:1065-1073.
14. Irwin S (1968) Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia 13:222-257.
15. Jacobson PB, Morgan S, Wilcox D, Nguyen P, Ratajczak C, Carlson R, Harris RR, Luo Y, and Nuss M (1999) A new spin on an old model, In vivo evaluation of the disease progression by MRI with respect to standard inflammatory parameters and histopathology. Arthritis Rheum 42:2060-2073.
16. Jarvis MF, Yu H, Kohlhaas K, Alexander K, Lee CH, Jiang M, Bhagwat SS, Williams M, and Kowaluk EA (2000) ABT-702 (4-amino-5-(3-bromophenyl)-7-(6- morpholinopyridin-3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse J Pharmacol Exp Ther 295:1156-1164.
17. Koki A, Khan NK, Woerner BM, Dannenberg AJ, Olson L, Seibert K, Edwards D, Hardy M, Isakson P, and Masferrer JL (2002) Cyclooxygenase-2 in human pathological disease. Adv Exp Med Biol 507:177-184.
18. Laufer S, Zechmeister P, and Klein T (1999) Development of an in vitro test system for the evaluation of cyclooxygnease-2 inhibitors. Inflamm Res 48:133-138.
19. Luong C, Miller A, Barnett J, Chow J, Ramesha C, and Browner MF (1996) Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol 3:927-933.
20. Pairet M and Engelhardt G (1996) Distinct isoforms of cyclooxygenases: possible physiological and therapeutic implications. Fundam Clin Pharmacol 10:1-15.
21. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, Cipollone F, Ganci A, Creminon C, Maclouf J, et al. (1994) Biochemical and pharmacological characterization of the cyclooxygenase activity of blood prostaglandin endoperoxide synthetase. J Pharmacol Exp Ther 271:1705-1712.
22. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, et al. (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H- pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J Med Chem 40:1347-1365.
23. Picot D, Loll PJ, and Garavito RM (1994) The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature (Lond) 367:243-249.
24. Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Ethier D, Falgueyret JP, Friesen RW, Gordon R, Greig G, et al. (2001) Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 296:558-566.
25. Segwick AD, Sin YN, Edwards JCW, and Willoughby DA (1983) Increased inflammatory reactivity in newly formed lining tissue. J Pathol 141:483-495.
26. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, Lee L, and Isakson P (1994) Pharmacological and Biochemical Demonstration of the Role of Cyclooxygenase-2 in Inflammation and Pain. Proc Natl Acad Sci USA 91:12013-12017.
27. Smith WL (1992) Prostanoid biosynthesis and mechanisms of action. Am J Physiol 263:F181-F191.
28. Stoerk HC, Bielinski TC, and Budzilovich T (1954) Chronic polyarthritis in rats injected with spleen in adjuvants. Am J Pathol 30:616-621.
29. Weichman BM (1989) Rat adjuvant arthritis: a model of chronic inflammation, in Pharmacological Methods in the Control of Inflammation (Chang JY and Lewis AJ eds) pp 363-380, Alan Liss Inc., New York.
30. Winter CA, Risley EA, and Nuss GW (1962) Carrageenan-induced edema in hind paw of the rat as an assay for anti-inflammatory drugs. Proc Soc Exp Biol Med 111:544-547.
31. Xie W, Robertson D, and Simmons D (1992) Mitogen-inducible prostaglandin g/h synthase: a new target for nonsteroidal anti-inflammatory drugs. Drug Dev Res 25:249-265.